|
|
Home > Healthcare > Pharmaceutical > Drug Discovery
SPECIAL REPORT: Understanding Treatment Dynamics and Needs in Juvenile Idiopathic Arthritis
|
| Published Date:
June 2009
Published By:
Decision Resources
Page Count:
25
Order Code:
R55-649
|
|
|
|
Introduction
Although interviewed thought leaders acknowledge that available biological therapies have greatly
improved treatment of juvenile idiopathic arthritis (JIA)—the most common rheumatic disease
in children—they do not hesitate to point out unmet needs and remaining drug development
opportunities in this field. When current treatments fail, severe disability and even death can result.
The heterogeneous nature of JIA leaves room for drugs that target new targets while meeting the
particular needs of the pediatric population.
Questions Answered in This Report
- JIA is an umbrella term for seven distinct diagnoses. How are the various JIA subtypes defined?
How are they diagnosed? How does their treatment differ?
- The drugs used in the treatment of JIA are identical to those used in adult rheumatic diseases.
What are the first-line therapies for JIA? What factors drive prescribing decisions? How safe
and efficacious are these treatments in children?
- Not all JIA patients are sufficiently treated with available therapies. Which specific unmet needs
remain? What agents are in development for JIA? How will these agents fit into the treatment
patterns for these diseases? What do thought leaders say about emerging agents?
Scope
- Overview of JIA: Oligoarthritis; polyarthritis; enthesitis-related arthritis; psoriatic
arthritis; systemic JIA; diagnosis of JIA.
- Epidemiology: Ten-year forecast for United States, France, Germany, Italy, Spain, United
Kingdom, and Japan.
- Current therapies: nonsteroidal anti-infl ammatory drugs (NSAIDs); corticosteroids;
methotrexate; tumor necrosis factor-alpha (TNF-á) inhibitors; Orencia; Kineret; Rituxan.
- Emerging therapies: Rilonacept; canakinumab; tocilizumab.
- Opportunities in JIA: Qualitative market outlook for current and emerging agents; unmet
needs.
- Primary research: Thought-leader interviews from the United States, France, Germany,
and the United Kingdom.
|
Similar Products
• Prostate Cancer Drug Discoveries: What the Future Holds
Published Nov 2009 by Espicom Healthcare Intelligence
• Competitor Analysis: Thrombopoiesis-Stimulating Agents (TPO)
Published Nov 2009 by La Merie S.L.
• Competitor Analysis: FSH, hCG and LH - Therapeutic Proteins for Assisted Reproductive Technology (ART)
Published Nov 2009 by La Merie S.L.
• Competitor Analysis: FGF-R Agonists and Antagonists
Published Nov 2009 by La Merie S.L.
• BI for Drug Development: Oracle Introduces Clinical Development Analytics
Published Nov 2009 by IDC
• Canada's Pharmaceutical Industry - Porter’s Five Forces Strategy Analysis
Published Nov 2009 by Aruvian's R'search
• Competitor Analysis: TGF-R Agonists and Antagonists
Published Nov 2009 by La Merie S.L.
• Protein Kinase Therapeutics in Oncology - Where to Commercialize?
Published Oct 2009 by BioSeeker Group AB
• CDK Inhibitors Patent Landscape 2009
Published Oct 2009 by France Innovation Scientifique et Transfer
• Antidiabetics in Australia Market Forecast
Published Oct 2009 by Datamonitor
|
|
|
|
0 items
